The OlympiA trial was a randomized, double-blind, phase III study of patients with HER2-negative, BRCA1/2 germline pathogenic or likely pathogenic variants and a high risk of recurrence of early BC [67]. This evidence concerns the gene BRCA1 and breast cancer.